Loading...
  • progression
  • In this case, ART should be continued (AI) with regimens designed to minimize toxicity, preserve CD4 cell counts, and delay clinical progression. (nih.gov)
  • Discontinuing or briefly interrupting therapy may lead to a rapid increase in HIV RNA, a decrease in CD4 cell count, and an increase in the risk of clinical progression. (nih.gov)
  • When complete virologic suppression cannot be achieved, the goals of therapy are to preserve or restore immunologic function (as measured by CD4 T lymphocyte values), prevent clinical disease progression, and prevent development of additional drug resistance that could further limit future ARV options (AII) . (nih.gov)
  • Clinical failure is defined as the occurrence of new opportunistic infections and/or other clinical evidence of HIV disease progression during therapy. (nih.gov)
  • fever
  • Comparison of viraemia- and clinical-based estimates of within- and between-pen transmission of classical swine fever virus from three transmission experiments. (semanticscholar.org)
  • Clinical signs appeared in 26 calves, 6-7 months old, and consisted of fever (39.4°-40.1°C), cough, accelerated pulse and breath, seromucoid nasal discharge, and leukopenia. (cdc.gov)
  • Clinical sighs of BT disease are mainly attributable to vascular permeability and include fever, hyperaemia and congestion, facial oedema and haemorrhages, and erosion of the mucous membranes. (scribd.com)
  • signs
  • Clinical signs and viraemia in Dorset Poll sheep vaccinated with BTV-4 and BTV-16 MLVs or inoculated with homogenates of midges (C. sonorensis and C. nubeculosus) previously infected with BTV-4 MLV are presented. (surrey.ac.uk)
  • therefore
  • The goal of this article, therefore, is to review available clinical diagnostics for YFV, which may not be familiar to many practitioners outside areas where it is endemic. (stanford.edu)
  • available
  • When it is not possible to construct a viable suppressive regimen for a patient with multidrug resistant HIV, the clinician should consider enrolling the patient in a clinical trial of investigational agents or contacting pharmaceutical companies that may have investigational agents available. (nih.gov)
  • Reverse-transcription polymerase chain reaction (RT-PCR) technology has permitted rapid amplification of BTV and EHDV RNA in clinical samples, and RT-PCR-based procedures are now available. (scribd.com)